Rosopatamab (HJ 591) is a humanised anti-PSMA monoclonal antibody that can be used in cancer research, particularly in prostate cancer[1][2].
[1]. Keun Ho Lee, et al. Antibody-payload conjugates with enhanced delivery domain and uses thereof. Patent WO2021092672A1.
[2]. Antonini P, et al. 177Lu-DOTA-TLX591 safety, biodistribution and dosimetry study (ProstACT-SELECT)[J]. 2022.
















